Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00003604|
Recruitment Status : Unknown
Verified September 2000 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : July 16, 2004
Last Update Posted : November 6, 2013
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells.
PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients with stage III or stage IV kidney cancer that has been removed by surgery.
|Condition or disease||Intervention/treatment||Phase|
|Kidney Cancer||Biological: aldesleukin||Phase 2|
OBJECTIVES: I. Determine the disease free survival and overall survival of patients with resected stage III or IV renal cancer treated with interleukin-2. II. Measure the degree of rebound lymphocytosis generated by this regimen in these patients.
OUTLINE: This is an open label study. Patients receive interleukin-2 IV over 15-30 minutes on 3 consecutive days weekly for 6 weeks, followed by 2 weeks of rest. Patients receive 2 treatment courses, each 8 weeks in duration. Patients are followed every 6 months until death.
PROJECTED ACCRUAL: A total of 20 patients will be accrued within 1 to 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Official Title:||A Multi-Center Adjuvant Trial of Outpatient Moderate-Dose Bolus Interleukin-2 for Renal Cancer|
|Study Start Date :||October 1997|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003604
|United States, Indiana|
|Cancer Care Center for Southern Indiana|
|Bloomington, Indiana, United States, 47403|
|United States, Nebraska|
|Bergan Mercy Medical Center|
|Omaha, Nebraska, United States, 68124|
|United States, Tennessee|
|Baptist Regional Cancer Center - Knoxville|
|Knoxville, Tennessee, United States, 37901|
|Study Chair:||Datchen F. Tai, MD||Cancer Biotherapy Research Group|